share_log

TD Cowen Maintains Outperform on BioLife Solns, Lowers Price Target to $25

Benzinga ·  Aug 9, 2023 16:16

TD Cowen analyst Max Masucci maintains BioLife Solns (NASDAQ:BLFS) with a Outperform and lowers the price target from $29 to $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment